NEWS & ANALYSIS
Selected inspection findings and source briefings, with a clear connection to practical questions.
Dates refer to the original sources.
Regulatory Watch
PIC/S PI 058-1 interprets the revised EU GMP Annex 1 (2022). For cleaning validation the key points are chemical residue control in isolators and RABS, the separation of cleaning from bio-decontamination, and why VHP surface bio-decontamination is not automatically sterilisation.
Read the analysis
Deep Analysis
Two years of regulatory revision, enforcement, new standards, tighter analytics and a first serious statistics stack have moved cleaning validation out of the appendix and into the centre of GMP. Five developments define where the field stands in September 2026 — and each one changes something a programme owner has to decide.
Read the briefing
Deep Analysis
At-line TOC, in-line UV and automated process capability monitoring are moving cleaning data from a laboratory result reported days later to a signal produced during the cycle. A close reading of what is proven, what standards actually require, and what remains a promising research proposal.
Read the briefing
Deep Analysis
Biologics degrade under cleaning, ADCs split one residue into antibody, linker, payload and conjugate, and peptide APIs combine high potency with methods already under strain. A synthesis of the local evidence on why toxicology, cleaning and detectability now move together.
Read the briefing
Deep Analysis
Visual inspection was present in every one of the cleaning findings FDA issued between 2024 and 2026 — never as the accused technique, always as the whole of the evidence. The distinction between a qualified visual method and a visual-only release decision is the difference between a control and an assumption.
Read the briefing
Deep Analysis
The analytical method is not a laboratory preference — it is the part of the cleaning validation strategy that decides whether a limit is actually measurable. The useful question is not which technique is 'best' but which technique matches the residue, the acceptance limit, the sampling method and the surface. This analysis walks through the trade-offs using published recovery, detection and clearance data, and shows why a method chosen before the residue is characterised tends to fail at the limit rather than at the bench.
Read the briefing
Deep Analysis
The three-run cleaning validation was never a requirement — it was the convention that grew where guidance was silent. PI 006-4, the ASTM cleaning standards and three recent FDA warning letters all point at the same thing: what has to be maintained is a validated state, and continued cleaning verification is how you know it still holds.
Read the briefing
Deep Analysis
A maximum allowable carry-over value is a PDE multiplied by a set of process assumptions — batch size, dose, surface area, recovery and the cleaning step itself. Read as a body of evidence, the 2025–2026 enforcement record is rarely about toxicity assessment, and almost always about those assumptions.
Read the briefing
Regulatory Watch
PIC/S has published PI 006-4, the revised Recommendations on Qualification and Validation, superseding the 2007 PI 006-3 and entering into force on 1 October 2026. Cleaning validation now occupies a full chapter, with HBEL-driven scope, explicit limits on visual inspection and a clear position against continued test-until-clean practice.
Read the briefing
Inspection Watch
FDA connects unvalidated cleaning on shared equipment with interim measures and the assessment of distributed products.
Read the briefing
Inspection Watch
A 2026 FDA warning letter to Dabur India rejects a shared-equipment cleaning programme that relied exclusively on visual inspection. The objection is narrower than it appears — and it turns on missing quantitative limits, not on visual inspection itself.
Read the briefing
Deep Analysis
Twelve FDA warning letters issued between 3 December 2024 and 24 July 2026 cite cleaning and cross-contamination control. Read together rather than case by case, they stop looking like twelve incidents and start looking like one audit checklist: worst-case selection, hold times, recovery, MACO justification, visual-only strategies, sampling locations, change control and lifecycle management — in that order of frequency.
Read the briefing
Regulatory Watch
EMA and PIC/S reissued the January 2026 Annex 15 concept paper in July 2026 with a new reference number and a substantially longer timetable. Nothing about cleaning validation itself changed — but the dates most teams are planning against did.
Read the briefing
Technology Watch
Antibody-drug conjugates combine a biologic, a chemical linker and a cytotoxic payload on shared equipment. A STERIS webinar frames the problem; independent guidance shows why one product-specific assay no longer answers the question.
Read the briefing
Regulatory Watch
An evergreen source briefing on the distinction between the safety basis and routine cleaning limits.
Read the briefing
Inspection Watch
FDA's 1 May 2026 warning letter to Harbin Jixianglong Biotech found a cleaning procedure that required a toxicity-based carryover limit, and a validation study that established none — with no justification for swab locations and no swab results.
Read the briefingInspection Watch
Observed residues and the response to them put cleaning effectiveness and product-impact assessment in focus.
Read the briefing
Research Watch
A comparative review in the PDA Journal weighs worst-case matrices against product-specific validation and proposes a hybrid model anchored on visible residue limits.
Read the briefingInspection Watch
A visible-residue observation illustrates the gap between a clean-status label and demonstrated cleaning effectiveness.
Read the briefingInspection Watch
An FDA investigator found white residue inside Tank #68 at Chemco Corporation — equipment the quality unit had already verified as clean. The finding itself is mundane. What it exposes about release decisions, shared equipment and the absence of cleaning validation is not.
Read the briefing
Inspection Watch
The letter links equipment cleaning, drying and microbial contamination risk in sterile manufacturing.
Read the briefingRegulatory Watch
A joint EMA–PIC/S concept paper proposes extending Annex 15 to active substance manufacturers and aligning it with ICH Q9(R1). The current Annex 15 stays in force, and the earliest a revised text could be published is 2028.
Read the briefingInspection Watch
FDA's Warning Letter 320-26-43 to Cosmetic Manufacturers (Aust) Pty Ltd. states that the firm's cleaning validation protocol 'was not designed to demonstrate reproducibility'. The cause is a design flaw that is easy to copy by accident: each qualification run sampled a different set of locations, so the runs were never replicates of the same measurement.
Read the briefing
Inspection Watch
FDA Warning Letter 320-26-40 to Cohance Lifesciences did not turn on a single residue number. It turned on whether the firm's verification programme could have found the carryover at all — and whether its worst-case basis was ever revisited.
Read the briefingResearch Watch
A January 2026 AAPS PharmSciTech paper proposes normalising every residue result to a percentage of its own specification limit, so that cleaning data from different products can finally be pooled, analysed non-parametrically and monitored as a Stage 3 capability index. The statistical argument is the substance; the AI framing is thinner than the title suggests.
Read the briefing
Inspection Watch
FDA's December 2025 letter to Medinatura New Mexico records a firm acknowledging that its cleaning validation was not reflective of current operations after years of buying new equipment and adding new products. What the gap looks like from the inside — and what it asks of change control.
Read the briefingIndustry Watch
A BeNeLux ISPE event on 23 September 2025 put 'business continuity' and 'culture' next to 'compliance' in the same talk title. That framing is the story: cleaning validation is being repositioned as an operational capability that keeps multi-product campaigns running, not a documentation obligation discharged before an inspection.
Read the briefing
Inspection Watch
The FDA's August 2025 warning letter to ABBE Laboratories describes a 2009 cleaning validation still standing while a harder-to-clean product was introduced onto the same shared kettle — and no change-control step that caught it.
Read the briefingTechnology Watch
A STERIS-authored article in Pharmaceutical Technology reports that in-line UV spectrometry at 220 nm can follow a biopharmaceutical cleaning cycle continuously, from heavily soiled rinse to baseline. The data are encouraging, the framing is vendor-supplied, and the distance between process monitoring and a release decision is where our own thinking has to do the work.
Read the briefing
Research Watch
A 2025 DARU Journal of Pharmaceutical Sciences study builds a structured cleaning-validation protocol for QC-lab glassware and stainless-steel equipment, using oxcarbazepine as worst-case API and pairing HPLC residue analysis with conductivity and TOC detergent checks.
Read the briefing
Standards Watch
ASTM International has published E3470-25, a first-edition guide on using FMECA and HACCP/HARPC to identify, analyse and control risk in pharmaceutical and medical device cleaning processes. It is the method layer that E3106 required but did not fully specify.
Read the briefing
Standards Watch
ASTM has re-issued E3219 as E3219-25, the current reference for deriving health-based exposure limits. HBELs are a decade-old regulatory expectation, not a 2025 novelty — but the revision sharpens how limits are derived, documented and defended.
Read the briefingTechnology Watch
TOC can live on the QC bench, on the shop floor next to the vessel, or plumbed into the CIP skid. The instrument is the same; the sampling chain — and therefore the meaning of the number — is not.
Read the briefingIndustry Watch
A lightning talk at PDA Week 2025 argued for a lean approach to analytical panels in cleaning validation. The independent framework to justify it already exists in ASTM E3106 and ICH Q9(R1) — but only if the arithmetic is documented.
Read the briefingIndustry Watch
INTERPHEX 2025 in New York put cleaning validation on the process-monitoring agenda: a dedicated panel on analytics, contamination control and sustainability, plus cleanroom and environmental-monitoring sessions. Industry-press report from Javits Center, 1-3 April 2025.
Read the briefingInspection Watch
A March 2025 FDA warning letter to Aspen Biopharma Labs Private Limited records investigators finding manufacturing equipment labelled "Cleaned" while liquid with a floating substance or residue remained on product-contact surfaces. That gap between a status tag and physical reality is one of the most consequential — and most preventable — failures in cleaning validation.
Read the briefing
Inspection Watch
The FDA rejected a retrospective MACO argument in a February 2025 warning letter — not because the arithmetic was wrong, but because the cleaning it assumed had not been performed. What cleaning-validation teams can take from it.
Read the briefingInspection Watch
In Warning Letter 320-25-38 the FDA did not attack visual inspection as a technique. It objected to a cleaning programme in which visual inspection was the only evidence on the table — no acceptance criteria for carryover residues, no analytical data, and no procedures for the rest of the equipment train.
Read the briefing
Research Watch
A NIPER-Ahmedabad group pairs a validated RP-HPLC surface-residue method for three SGLT-2 inhibitors with a detoxification strategy for the resulting cleaning waste.
Read the briefingInspection Watch
A December 2024 warning letter to Brands International Corporation cites the firm under 21 CFR 211.67(b) for failing to perform cleaning validation studies on non-dedicated equipment — and asks for a cleaning programme built around worst-case products, worst-case swab sites and maximum hold times before cleaning.
Read the briefingInspection Watch
An FDA Warning Letter to Indian API manufacturer Micro Orgo Chem describes non-dedicated equipment that had never been cleaned under a validated procedure, cleaning SOPs that were not followed, and no evidence that the rinse and swab samples required by the firm's own procedure were ever collected or tested.
Read the briefingStandards Watch
ASTM work item WK92658 wants to standardise how cleaning processes are judged capable — one-sided limits, small data sets, non-normal residues and continued verification included. It is the statistical gap E3106 left open.
Read the briefing
Research Watch
A bench-scale study puts the 650 ug/dose parenteral PDE for cleaning-induced protein degradants to the test with human-cell immunogenicity assays on HLE BiTE and mAb degradants, spiked into the same and a cross product.
Read the briefingStandards Watch
ASTM Work Item WK92599 would give total organic carbon analysis its own dedicated guidance for swab and rinse samples — and force cleaning programmes to defend recovery and limits, not just concentrations.
Read the briefing
Research Watch
A German hospital-pharmacy study argues blister-machine cleaning is a mandatory duty of care, and shows UV-Vis spectroscopy can replace HPLC as the analytical method.
Read the briefing